Clinical Trials - April 20, 2021
Novo Nordisk expands collaboration with Gilead
Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and […]
Clinical Trials - December 28, 2020
Novo Nordisk to enter phase 3 development in Alzheimer’s disease
Novo Nordisk has announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions […]
Acquisition - November 11, 2020
Novo Nordisk to acquire Emisphere Technologies for USD 1.8 billion
Novo Nordisk has entered into a definitive agreement to acquire Emisphere Technologies, a drug delivery company with technologies such as the Eligen SNAC technology, that enable oral formulations of therapeutics. Novo Nordisk and Emisphere have collaborated since 2007 and Emisphere’s drug delivery technology Eligen SNAC is used by Novo Nordisk under an existing licence agreement […]
Collaboration - October 29, 2020
Novo Nordisk joins Medicon Valley Alliance
Medicon Valley Alliance is to welcome Novo Nordisk Scandinavia and General Manager & VP, Novo Nordisk Scandinavia, Niels Abel Bonde to the +300 member strong Danish-Swedish MVA-family. A strategic priority “We consider it a strategic priority to be a part of the Swedish and Medicon Valley based life science eco-system. Medicon Valley Alliance is working […]
Pharma article - September 24, 2020
Novo Nordisk launches 100% renewable power target for suppliers
Novo Nordisk has announced a target to ensure all its direct suppliers supply the company based on 100% renewable power by 2030. Novo Nordisk will work with all existing and new suppliers to meet the target. The plan will be presented in connection with Climate Week NYC. Circular for Zero This commitment is the next […]
Clinical Trials - September 24, 2020
Results from the world’s largest study of cardiovascular disease in type 2 diabetes
Novo Nordisk has announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first of its kind and involving nearly 10,000 participants from 13 countries across five continents, showed that 1 in […]
